Contribution of chitosan and its derivatives to cancer chemotherapy

In Vivo

Volumn 19, Issue 1, 2005, Pages 301-310

  Kato, Yoshinori ^a   Onishi, Hiraku ^b   Machida, Yoshiharu ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

6 O carboxymethyl chitin; Anticancer agents; Antitumour activity; Biodistribution; Chitosan; Glyco chitosan; N succinyl chitosan; Review

Indexed keywords

6 O CARBOXYMETHYL CHITIN; ANTINEOPLASTIC AGENT; CHITIN DERIVATIVE; CHITOSAN DERIVATIVE; CYTARABINE; DOXIFLURIDINE; DRUG CARRIER; GLYCOL CHITOSAN; MITOMYCIN C; N SUCCINYL CHITOSAN; POLYMER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG TISSUE LEVEL; GROWTH INHIBITION; KIDNEY TUBULE ABSORPTION; LEUKEMIA; LIVER CANCER; NONHUMAN; REVIEW; SOLID TUMOR; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE; SYSTEMIC CIRCULATION; TUMOR GROWTH; TUMOR MODEL;

EID: 16244400529     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Ouchi T, Banba T, Matsumoto T, Suzuki S and Suzuki M: Synthesis and antitumor activity of conjugates of 5-fluorouracil and chito-oligosaccharides involving a hexamethylene spacer group and carbamoyl bonds. Drug Des Deliv 6: 281-287, 1990.
2. Hassan EE, Parish RC and Gallo JM: Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm Res 9: 390-397, 1992.
3. Ohya Y, Takei T, Kobayashi H and Ouchi T: Release behaviour of 5-fluorouracil from chitosan-gel microspheres immobilizing 5-fluorouracil derivative coated with polysaccharides and their cell specific recognition. J Microencapsul 10(1): 1-9, 1993.
4. Sanzgiri YD, Balanton CD Jr and Gallo JM: Synthesis, characterization, and in vitro stability of chitosan-methotrexate conjugates. Pharm Res 7(4): 418-421, 1990.
5. Onishi H, Nagai T and Machida Y: Conjugates of drugs with chitosan and N-succinylchitosan. In: Chitin Handbook (Muzzarelli RAA and Peter MG, eds). Italy, European Chitin Society, 1997, pp 383-389.
6. Onishi H, Kato Y, Hata H and Machida Y: Biological fates of N-succinylchitosan and 6-O-carboxymethylchitin after intravenous injection in mice. In: Chitin and Chitosan - Chitin and Chitosan in Life Science - (Uragami T, Kurita K and Fukamizo T, eds). Tokyo, Kodansha Scientific Ltd., 2000, pp 206-209.
7. Onishi H and Machida Y: In vivo biological fates of water-soluble chitin- and chitosan-related polymers. In: Recent Research Developments in Comparative Biochemistry and Physiology 2 (Pandalai SG, ed). Kerala, India, Transworld Reasearch Network, 2001, pp 1-15.
8. Kato Y, Onishi H and Machida Y: Application of chitin and chitosan derivatives in the pharmaceutical field. Curr Pharm Biotechnol 4(5): 303-309, 2003.
9. Kato Y, Onishi H and Machida Y: N-succinyl-chitosan as a drug carrier: water-insoluble and water-soluble conjugates. Biomaterials 25: 907-915, 2004.
10. Davies RC, Neuberger A and Wilson BM: The dependence of lysozyme activity on pH and ionic strength. Biochim Biophys Acta 178(2): 294-305, 1969.
11. Amano K and Ito E: The action of lysozyme on partially deacetylated chitin. Eur J Biochem 85(1): 97-104, 1978.
12. Pangburn SH, Trescony PV and Heller J: Lysozyme degradation of partially deacetylated chitin, its films and hydrogels. Biometerials 3(2): 105-108, 1982.
13. Nishimura S, Nishi N, Tokura S, Nishimura K and Azuma I: Bioactive chitin derivatives. Activation of mouse-peritoneal macrophages by O-(carboxymethyl)chitins. Carbohydr Res 146(2): 251-258, 1986.
14. Yomota C, Komuro T and Kimura T: Studies on the degradation of chitosan films by lysozyme and release of loaded chemicals. Yakugaku Zasshi 110(6): 442-448, 1990.
15. Nakamura F, Onishi H, Machida Y and Nagai T: Lysozyme-catalyzed degradation properties of the conjugates between chitosans having some deacetylation degrees and methotrexate. Yakuzaigaku 52: 59-67, 1992.
16. Onishi H and Machida Y: Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials 20: 175-182, 1999.
17. Lee KY, Ha WS and Park WH: Blood compatibility and biodegradability of partially N-acetylated chitosan derivatives. Biomaterials 16: 1211-1216, 1995.
18. Carreno-Gomez B and Duncan R: Evaluation of the properties of soluble chitosan and chitosan microspheres. Int J Pharm 148: 231-240, 1997.
19. Yoshino T, Machida Y, Onishi H and Nagai T: Characteristics of drug loading, drug release and degradation of chitosan microspheres prepared using the dry-in-oil method. STP Pharma Sci 6: 122-128, 1996.
20. Jameela SR, Kumary TV, Lal AV and Jayakrishnan A: Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system. J Control Release 52: 17-24, 1998.
21. Yoshino T, Machida Y, Onishi H and Nagai T: Preparation and characterization of chitosan microspheres containing doxifluridine. Drug Dev Ind Pharm 29: 417-427, 2003.
22. Song Y, Onishi H and Nagai T: Synthesis and drug-release characteristics of the conjugates of mitomycin C with N succinyl-chitosan and carboxymethyl-chitin. Chem Pharm Bull 40: 2822-2825, 1992.
23. Song Y, Onishi H and Nagai T: Conjugate of mitomycin C with N-succinyl-chitosan-mitomycin C: in vitro drug release properties, toxicity and antitumor activity. Int J Pharm 98: 121-130, 1993.
24. Song Y, Onishi H and Nagai T: Toxicity and antitumor activity of the conjugate of mitomycin C with carboxymethyl-chitin. Yakuzaigaku 53: 141-147, 1993.
25. Kamiyama K, Onishi H and Machida Y: Biodisposition characteristics of N-succinyl-chitosan and glycol-chitosan in normal and tumor-bearing mice. Biol Pharm Bull 22: 179-186, 1999.
26. Kato Y, Onishi H and Machida Y: Evaluation of N succinyl-chitosan as a systemic long-circulating polymer. Biomaterials 21: 1579-1585, 2000.
27. Chu BC and Howell SB: Pharmacological and therapeutic properties of carrier bound methotrexate against tumor confined to a third space body compartment. J Pharmacol Exp Ther 219: 389-393, 1981.
28. Trouet A, Masquelier M, Baurain R and Deprez-De Campeneere D: A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci USA 79: 626-629, 1982.
29. Hashida M, Takakura Y, Matsumoto S, Sasaki H, Kato A, Kojima T, Muranishi S and Sezaki H: Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Chem Pharm Bull 31 2055-2063, 1983.
30. Takakura Y, Takagi A, Hashida M and Sezaki H: Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm Res 4: 293-300, 1987.
31. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T and Tsujihara K: Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res 60: 2988-2995, 2000.
32. Greenwald RB, Choe YH, McGuire J and Conover CD: Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55: 217-250, 2003.
33. Nishida K, Mihara K, Takino T, Nakane S, Takakura Y, Hashida M and Sezaki H: Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm Res 8: 437-444, 1991.
34. Song Y, Onishi H and Nagai T: Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate. Biol Pharm Bull 16: 48-54, 1993.
35. Harada M, Sakakibara H, Yano T, Suzuki T and Okuno S: Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J Control Release 69: 399-412, 2000.
36. Kato Y, Onishi H and Machida Y: Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Release 70: 295-307, 2001.
37. Kato Y, Onishi H and Machida Y: Efficacy of lactosaminated and intact N-succinyl-chitosan-mitomycin C conjugates against M5076 liver metastatic cancer. J Pharm Pharmacol 54: 529-537, 2002.
38. Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 46 6387-6392, 1986.
39. Seymour LW: Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135-187, 1992.
40. Maeda H: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41: 189-207, 2001.
41. Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J and Duncan R: Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer 70: 636-641, 1994.
42. Hosoda J, Unezaki S, Maruyama K, Tsuchiya S and Iwatsuru M: Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes. Biol Pharm Bull 18: 1234-1237, 1995.
43. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y and Kataoka K: Development of the polymer micelle carrier system for doxorubicin. J Control Release 74: 295-302, 2001.
44. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A and Maruyama HB: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 71: 112-123, 1980.
45. Suzuki S, Hongu Y, Fukazawa H, Ichihara S and Shimizu H: Tissue distribution of 5′-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats. Gann 71: 238-245, 1980.
46. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishitsuka H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull 31: 175-178, 1983.
47. Ichikawa H, Onishi H, Sato M, Machida Y and Nagai T: Preparation and evaluation of the macromolecular conjugate of 2′ or 3′-(4-carboxybutyryl)doxifluridine with chitosan. Yakuzaigaku 55: 59-69, 1995.
48. Onishi H, Machida Y and Nagai T: Synthesis and properties of the monoesters of 5-fluorouridine with 4-carboxybutyric acid and their conjugates with chitosan. Chem Pharm Bull 43: 340-343, 1995.
49. Shimoyama M and Kimura K: Quantitative study on cytocidal action of anticancer agents. Saishin Igaku 28: 1024-1040, 1973.
50. 4-acyl-1-beta-D-arabinofuranosylcytosine. Cancer Res 36: 2726-2732, 1976.
51. Kato Y, Saito M, Fukushima H, Takeda Y and Hara T: Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Cancer Res 44: 25-30, 1984.
52. 4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res 37: 2481-2486, 1977.
53. 4-(4-carboxybutyryl)-ara-C with ethylenediamine-introduced dextran and its resistance to cytidine deaminase. Drug Des Deliv 6: 273-280, 1990.
54. Onishi H, Seno Y, Pithayanukul P and Nagai T: Conjugate of ethylenediamine introduced dextran. Drug release profiles and further in vivo study of its antitumor effects. Drug Des Deliv 7: 139-145, 1991.
55. 4-(4-carboxybutyryl)-1-β-D-arabinofuranosylcytosine and its conjugate with poly-L-lysine or decylenediamine-dextran T70. Chem Pharm Bull 37 1587-1590, 1989.
56. 4-(4-carboxybutyryl)-1-β-D-arabinofuranosylcytosine. Drug Des Discov 10: 343-353, 1993.
57. Sato M, Onishi H, Kitano M, Machida Y and Nagai T: Preparation and drug release characteristics of the conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Biol Pharm Bull 19: 241-245, 1996.
58. Kato Y, Tsukada Y, Hara T and Hirai H: Enhanced antitumor activity of mitomycin C conjugated with anti-alpha-fetoprotein antibody by a novel method of conjugation. J Appl Biochem 5: 313-319, 1983.
59. Sato M, Onishi H, Takahara J, Machida Y and Nagai T: In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N succinyl-chitosan. Biol Pharm Bull 19: 1170-1177, 1996.
60. Hata H, Onishi H and Machida Y: Evaluation of carboxymethylchitin as a drug carrier: effect of the deacetylation degree on the biodegradation and biodisposition characteristics in mice. STP Pharma Sci 9: 115-121, 1999.
61. Kato Y, Onishi H and Machida Y: A novel water-soluble N succinyl-chitosan-mitomycin C conjugate prepared by direct carbodiimide coupling: physicochemical properties, antitumor characteristics and systemic retention. STP Pharma Sci 10: 133-142, 2000.
62. Shirahata K: Basic studies-Chapter 1: Chemical; Section VI: Derivatives and activities. In: Mitomycin (Taguchi T, ed). Tokyo, Kyowa Kikaku Tsushin, 1984, pp 25-43.
63. Sezaki H and Hashida M: Macromolecule-drug conjugates in targeted cancer chemotherapy. Crit Rev Ther Drug Carrier Syst 1: 1-38, 1984.
64. Kato Y, Onishi H and Machida Y: Lactosaminated N succinyl-chitosan: preparation and biodistribution into the intestine, bone, lymph nodes and male genital organs after i.v. administration. Macromolecular Res 11: 382-386, 2003.
65. Kato Y, Onishi H and Machida Y: Biological fate of highly-succinylated N-succinyl-chitosan and antitumor characteristics of its water-soluble conjugate with mitomycin C at i.v. and i.p. administration into tumor-bearing mice. Biol Pharm Bull 23: 1497-1503, 2000.
66. Peluso G, Petillo O, Ranieri M, Santin M, Ambrosio L, Calabro D, Avallone B and Balsamo G: Chitosan-mediated stimulation of macrophage function. Biomaterials 15: 1215-1220, 1994.
67. Tokura S, Tamura H and Azuma I: Immunological aspects of chitin and chitin derivatives administered to animals. EXS 87: 279-292, 1999.
68. Song Y, Onishi H, Machida Y and Nagai T: Drug release and antitumor characteristics of N-succinyl-chitosan-mitomycin C as an implant. J Control Release 42: 93-100, 1996.
69. Kato Y, Onishi H and Machida Y: Tumour cell uptake of lactosaminated and intact N-succinyl-chitosans and antitumour effects of conjugates with mitomycin C. Anticancer Res 22: 2771-2776, 2002.